Hudson Bay Capital Management
GALT icon

Hudson Bay Capital Management’s Galectin Therapeutics GALT Stock Holding History

Hudson Bay Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-74,728
Closed -$208K – 1467
2026
Q1 		$208K Sell
74,728
-3,417
-4% -$10.4K ﹤0.01% 1093
2025
Q4 		$325K Buy
78,145
+63,319
+427% +$333K ﹤0.01% 912
2025
Q3 		$62.8K Buy
+14,826
New +$55.8K ﹤0.01% 1113

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Hudson Bay Capital Management's GALT Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 74,728 shares — an estimated $208K sold.

Hudson Bay Capital Management first reported a position in GALT in Q3 2025 and held it in 3 quarters. The position peaked at $325K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 74,728 Galectin Therapeutics shares in Q2 2026, an estimated $208K.
  • Hudson Bay Capital Management first reported a position in Galectin Therapeutics in Q3 2025 and held it in 3 quarters.
  • Hudson Bay Capital Management's Galectin Therapeutics position peaked at $325K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.